Mutation-selective tumor remission with Ras-targeted, whole yeast-based immunotherapy

Targeting RAS signalling pathways in cancer therapy

Downward, J. (2003) · Nature reviews. Cancer · doi:10.1038/nrc969 · Cited by 3,262 · see citing works

The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between Toll-like receptors

Ozinsky, A., Underhill, D. M., Fontenot, J. D., Hajjar, A. M., Smith, K. D., Wilson, C. B., Schroeder, L. A., & Aderem, A. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.250476497 · Cited by 2,086 · see citing works

RAS oncogenes: the first 30 years

Malumbres, M., & Barbacid, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1097 · Cited by 1,902 · see citing works

Dectin-1 Mediates the Biological Effects of β-Glucans

Brown, G. D., Herre, J., Williams, D. L., Willment, J. A., Marshall, A. S. J., & Gordon, S. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021890 · Cited by 1,209 · see citing works

BRAF and RAS mutations in human lung cancer and melanoma.

Brose, M. S., Volpe, P., Feldman, M. D., Kumar, M. S., Rishi, I., Gerrero, R. M., Einhorn, E., Herlyn, M., Minna, J. D., Nicholson, A. G., et al. (2002) · PubMed · Cited by 1,048 · see citing works

The Plasticity of Dendritic Cell Responses to Pathogens and Their Components

Huang, Q., Liu, D., Majewski, P., Schulte, L. C., Korn, J. M., Young, R. A., Lander, E. S., & Hacohen, N. (2001) · Science · doi:10.1126/science.294.5543.870 · Cited by 747 · see citing works

Activation of the Ki-ras protooncogene in spontaneously occurring and chemically induced lung tumors of the strain A mouse.

You, M., Candrian, U., Maronpot, R. R., Stoner, G. D., & Anderson, M. W. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.9.3070 · Cited by 336 · see citing works

Classification of Proliferative Pulmonary Lesions of the Mouse

Nikitin, A. Y., Alcaraz, A., Anver, M. R., Bronson, R. T., Cardiff, R. D., Dixon, D., Fraire, A. E., Gabrielson, E. W., Gunning, W. T., Haines, D. C., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3376 · Cited by 334 · see citing works

Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity

Stubbs, A. C., Martin, K. S., Coeshott, C. M., Skaates, S. V., Kuritzkes, D. R., Bellgrau, D., Franzusoff, A., Duke, R. C., & Wilson, C. C. (2001) · Nature Medicine · doi:10.1038/87974 · Cited by 208 · see citing works

Toll-like Receptors as Sensors of Pathogens

Hallman, M., Rämet, M., & Ezekowitz, R. A. B. (2001) · Pediatric Research · doi:10.1203/00006450-200109000-00004 · Cited by 146 · see citing works

Candida albicansIs Phagocytosed, Killed, and Processed for Antigen Presentation by Human Dendritic Cells

Newman, S. L., & Holly, A. (2001) · Infection and Immunity · doi:10.1128/iai.69.11.6813-6822.2001 · Cited by 146 · see citing works

Primary lung tumors in mice: an experimentally manipulable model of human adenocarcinoma.

Malkinson, A. M. (1992) · PubMed · Cited by 134 · see citing works

Primary lung tumors in mice as an aid for understanding, preventing, and treating human adenocarcinoma of the lung

Malkinson, A. M. (2001) · Lung Cancer · doi:10.1016/s0169-5002(00)00232-4 · Cited by 112 · see citing works

Yeast-Derived Human Immunodeficiency Virus Type 1 p55gagVirus-Like Particles Activate Dendritic Cells (DCs) and Induce Perforin Expression in Gag-Specific CD8+T Cells by Cross-Presentation of DCs

Tsunetsugu‐Yokota, Y., Morikawa, Y., Isogai, M., Kawana‐Tachikawa, A., Odawara, T., Nakamura, T., Grassi, M. F. R., Autran, B., & Iwamoto, A. (2003) · Journal of Virology · doi:10.1128/jvi.77.19.10250-10259.2003 · Cited by 82 · see citing works

The interaction of human dendritic cells with yeast and germ-tube forms of Candida albicans leads to efficient fungal processing, dendritic cell maturation, and acquisition of a Th1 response-promoting function

Romagnoli, G., Nisini, R., Chiani, P., Mariotti, S., Teloni, R., Cassone, A., & Torosantucci, A. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.0503226 · Cited by 69 · see citing works

A direct relationship between immune competence and the subcutaneous growth rate of a malignant murine lung tumor.

Yuhas, J. M., Pazmiño, N. H., Proctor, J. E., & Toya, R. E. (1974) · PubMed · Cited by 67 · see citing works

Specific Ki‐ras codon 61 mutations may determine the development of urethan‐induced mouse lung adenomas or adenocarcinomas

Nuzum, E. O., Malkinson, A. M., & Beer, D. G. (1990) · Molecular Carcinogenesis · doi:10.1002/mc.2940030509 · Cited by 67 · see citing works

Ki-ras gene mutations and absence ofp53 gene mutations in spontaneous and urethane-induced early lung lesions in CBA/J mice

Cazorla, M., Hernández, L., Fernández, P. L., Fabra, À., Peinado, M. A., Dasenbrock, C., Tillmann, T., Kamino, K., Campo, E., Köhler, M., et al. (1998) · Molecular Carcinogenesis · doi:10.1002/(sici)1098-2744(199804)21:4 · Cited by 34 · see citing works

Inhibition of protein kinase C and proto-oncogene expression by crocetin in NIH/3T3 cells

Wang, C., Cheng, T., Liu, J.-Y., Chou, F., Kuo, M., & Lin, J.-K. (1996) · Molecular Carcinogenesis · doi:10.1002/(sici)1098-2744(199612)17:4 · Cited by 28 · see citing works

Corrections

(2004) · Cancer Research · doi:10.1158/0008-5472.can-64-10-cor · Cited by 28 · see citing works

Serum levels of surfactant protein D are increased in mice with lung tumors.

Zhang, F., Pao, W. J., Umphress, S. M., Jakowlew, S. B., Meyer, A. M., Dwyer‐Nield, L. D., Nielsen, L. D., Takeda, K., Gelfand, E. W., Fisher, J. H., et al. (2003) · PubMed · Cited by 25 · see citing works

Mutation analysis of vinyl carbamate or urethane induced lung tumors in rasH2 transgenic mice

Tomisawa, M., Suemizu, H., Ohnishi, Y., Maruyama, C., Urano, K., Usui, T., Yasuhara, K., Tamaoki, N., & Mitsumori, K. (2003) · Toxicology Letters · doi:10.1016/s0378-4274(03)00018-3 · Cited by 24 · see citing works

Influence of Immunosuppression and Immunorestoration on the Formation of Urethan-induced Lung Adenomas 2

Trainin, N., & Linker‐Israeli, M. (1970) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/44.4.893 · Cited by 23 · see citing works

Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer

Zhu, G., Pei, L., Xia, H., Tang, Q., & Bi, F. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01441-4 · Cited by 482 · see citing works

Prognostic and Therapeutic Implications of EGFR and KRAS Mutations in Resected Lung Adenocarcinoma

Marks, J. L., Broderick, S., Zhou, Q. C., Chitale, D. A., Li, A. R., Zakowski, M. F., Kris, M. G., Rusch, V. W., Azzoli, C. G., Seshan, V., et al. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318160c607 · Cited by 268 · see citing works

K-ras as a target for cancer therapy

Friday, B. B., & Adjei, A. A. (2005) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2005.08.001 · Cited by 245 · see citing works

Yeast-based vaccines: New perspective in vaccine development and application

Kumar, R., & Kumar, P. (2019) · FEMS Yeast Research · doi:10.1093/femsyr/foz007 · Cited by 134 · see citing works

Customized materials-assisted microorganisms in tumor therapeutics

Chen, Q., Qiao, J., Liu, X., Zhang, C., & Zhang, X. (2021) · Chemical Society Reviews · doi:10.1039/d0cs01571g · Cited by 109 · see citing works

Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins

Haller, A. A., Lauer, G. M., King, T. H., Kemmler, C. B., Fiolkoski, V., Lu, Y., Bellgrau, D., Rodell, T. C., Apelian, D., Franzusoff, A., et al. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.10.035 · Cited by 106 · see citing works

Vaccines based on whole recombinant Saccharomyces cerevisiae cells

Ardiani, A., Higgins, J. P., & Hodge, J. W. (2010) · FEMS Yeast Research · doi:10.1111/j.1567-1364.2010.00665.x · Cited by 90 · see citing works

Kirsten Ras* oncogene: Significance of its discovery in human cancer research

Tsuchida, N., Murugan, A. K., & Grieco, M. (2016) · Oncotarget · doi:10.18632/oncotarget.8773 · Cited by 87 · see citing works

Protection against Experimental Cryptococcosis following Vaccination with Glucan Particles ContainingCryptococcusAlkaline Extracts

Specht, C. A., Lee, C. K., Huang, H., Tipper, D. J., Shen, Z. T., Lodge, J. K., Leszyk, J., Ostroff, G. R., & Levitz, S. M. (2015) · mBio · doi:10.1128/mbio.01905-15 · Cited by 85 · see citing works

Vaccination with a Recombinant Saccharomyces cerevisiae Expressing a Tumor Antigen Breaks Immune Tolerance and Elicits Therapeutic Antitumor Responses

Wansley, E. K., Chakraborty, M., Hance, K. W., Bernstein, M. B., Boehm, A. L., Guo, Z., Quick, D. M., Franzusoff, A., Greiner, J. W., Schlom, J., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0393 · Cited by 84 · see citing works

The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives

Takeda, M., Yoshida, S., Inoue, T., Sekido, Y., Hata, T., Hamabe, A., Ogino, T., Miyoshi, N., Uemura, M., Yamamoto, H., et al. (2025) · Cancers · doi:10.3390/cancers17030428 · Cited by 82 · see citing works

Cancer Vaccines: Preclinical Studies and Novel Strategies

Palena, C., Abrams, S. I., Schlom, J., & Hodge, J. W. (2006) · Advances in cancer research · doi:10.1016/s0065-230x(06)95004-0 · Cited by 81 · see citing works

Phase II Study of the GI-4000 KRAS Vaccine After Curative Therapy in Patients With Stage I-III Lung Adenocarcinoma Harboring a KRAS G12C, G12D, or G12V Mutation

Chaft, J. E., Litvak, A., Arcila, M. E., Patel, P., D'Angelo, S. P., Krug, L. M., Rusch, V., Mattson, A., Coeshott, C., Park, B., et al. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.06.002 · Cited by 78 · see citing works

Using Whole Genome Amplification (WGA) of Low-Volume Biopsies to Assess the Prognostic Role of EGFR, KRAS, p53, and CMET Mutations in Advanced-Stage Non-small Cell Lung Cancer (NSCLC)

Lim, E. H., Zhang, S.-L., Li, J., Yap, W. S., Howe, T.-C., Tan, B. P., Lee, Y.-S., Wong, D., Khoo, K., Seto, K., et al. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181913e28 · Cited by 76 · see citing works

Exploiting fungal cell wall components in vaccines

Levitz, S. M., Huang, H., Ostroff, G. R., & Specht, C. A. (2014) · Seminars in Immunopathology · doi:10.1007/s00281-014-0460-6 · Cited by 71 · see citing works

Tumor Signaling to the Bone Marrow Changes the Phenotype of Monocytes and Pulmonary Macrophages during Urethane-Induced Primary Lung Tumorigenesis in A/J Mice

Redente, E. F., Orlicky, D. J., Bouchard, R. J., & Malkinson, A. M. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.060566 · Cited by 71 · see citing works

Potential Targets for Pancreatic Cancer Immunotherapeutics

Dodson, L. F., Hawkins, W. G., & Goedegebuure, P. S. (2011) · Immunotherapy · doi:10.2217/imt.11.10 · Cited by 69 · see citing works

Recombinant Saccharomyces cerevisiae (yeast-CEA) as a potent activator of murine dendritic cells

Bernstein, M. B., Chakraborty, M., Wansley, E. K., Guo, Z., Franzusoff, A., Mostböck, S., Sabzevari, H., Schlom, J., & Hodge, J. W. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.11.033 · Cited by 69 · see citing works

Yeasts encoding tumour antigens in cancer immunotherapy

Franzusoff, A., Duke, R. C., King, T. H., Lu, Y., & Rodell, T. C. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.5.4.565 · Cited by 61 · see citing works

Suppression of lung cancer tumor growth in a nude mouse model by the Ras inhibitor salirasib (farnesylthiosalicylic acid)

Zundelevich, A., Elad‐Sfadia, G., Haklai, R., & Kloog, Y. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0706 · Cited by 58 · see citing works

Cancer vaccines: Targeting KRAS-driven cancers

Zhang, Y., Ma, J., Zhang, H.-X., Jiang, Y., & Luo, W. (2020) · Expert Review of Vaccines · doi:10.1080/14760584.2020.1733420 · Cited by 58 · see citing works

Antigen Release Kinetics in the Phagosome Are Critical to Cross-Presentation Efficiency

Howland, S. W., & Wittrup, K. D. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.3.1576 · Cited by 55 · see citing works

Saccharomyces cerevisiae: a versatile eukaryotic system in virology

Galão, R. P., Scheller, N., Alves‐Rodrigues, I., Breinig, T., Meyerhans, A., & Díez, J. (2007) · Microbial Cell Factories · doi:10.1186/1475-2859-6-32 · Cited by 57 · see citing works

Promises and challenges for the development ofListeria monocytogenes-based immunotherapies

Brockstedt, D. G., & Dubensky, T. W. (2008) · Expert Review of Vaccines · doi:10.1586/14760584.7.7.1069 · Cited by 47 · see citing works

Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future

Goel, G., & Sun, W. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0141-5 · Cited by 46 · see citing works

Reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutation: Report on initial experience and clinical utility at a single center

D’Angelo, S. P., Park, B. J., Azzoli, C. G., Kris, M. G., Rusch, V. W., Ladanyi, M., & Zakowski, M. F. (2010) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2010.08.026 · Cited by 42 · see citing works

Biomedical applications of yeast- a patent view, part one: yeasts as workhorses for the production of therapeutics and vaccines

Roohvand, F., Shokri, M., Abdollahpour‐Alitappeh, M., & Ehsani, P. (2017) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1339789 · Cited by 42 · see citing works

Saccharomycesas a Vaccine Against Systemic Candidiasis

Liu, M., Clemons, K. V., Johansen, M. E., Martinez, M., Chen, V., & Stevens, D. A. (2012) · Immunological Investigations · doi:10.3109/08820139.2012.692418 · Cited by 42 · see citing works

Protective Vaccination against Infectious Bursal Disease Virus with Whole Recombinant Kluyveromyces lactis Yeast Expressing the Viral VP2 Subunit

Arnold, M., Durairaj, V., Mundt, E., Schulze, K., Breunig, K. D., & Behrens, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042870 · Cited by 41 · see citing works

Whole recombinant Saccharomyces cerevisiae yeast expressing Ras mutations as treatment for patients with solid tumors bearing Ras mutations: Results from a phase 1 trial

Cohn, A., Morse, M. A., O’Neil, B., Whiting, S., Coeshott, C., Ferraro, J., Bellgrau, D., Apelian, D., & Rodell, T. C. (2018) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000219 · Cited by 41 · see citing works

An indoleamine 2, 3-dioxygenase siRNA nanoparticle-coated and Trp2-displayed recombinant yeast vaccine inhibits melanoma tumor growth in mice

Liu, D., Lü, S., Zhang, L. L., Ji, M., Liu, S., Wang, S., & Liu, R. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.01.013 · Cited by 39 · see citing works

Delivery of functional DNA and messenger RNA to mammalian phagocytic cells by recombinant yeast

Walch, B., Breinig, T., Schmitt, M., & Breinig, F. (2011) · Gene Therapy · doi:10.1038/gt.2011.121 · Cited by 38 · see citing works

Targeting KRAS in Colorectal Cancer

Wang, C., & Fakih, M. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01022-0 · Cited by 34 · see citing works

Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR

Whitsett, T. G., Richer, A. L., Friel, J. M., Carson, V. M., & Inge, L. J. (2015) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s52845 · Cited by 33 · see citing works

Animal vaccines based on orally presented yeast recombinants

Shin, M., & Yoo, H. S. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.07.029 · Cited by 33 · see citing works

Saccharomyces as a vaccine against systemic aspergillosis: ‘the friend of man’ a friend again?

Liu, M., Capilla, J., Johansen, M. E., Alvarado, D., Martinez, M., Chen, V., Clemons, K. V., & Stevens, D. A. (2011) · Journal of Medical Microbiology · doi:10.1099/jmm.0.033290-0 · Cited by 32 · see citing works

Gene delivery to dendritic cells by orally administered recombinant Saccharomyces cerevisiae in mice

Kiflmariam, M. G., Yang, H., & Zhang, Z. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.11.048 · Cited by 32 · see citing works

Enhancing anticancer activity of checkpoint immunotherapy by targeting RAS

Ward, A., Keeton, A. B., Chen, X., Mattox, T. E., Coley, A. B., Maxuitenko, Y. Y., Buchsbaum, D. J., Randall, T. D., Zhou, G., & Piazza, G. A. (2020) · MedComm · doi:10.1002/mco2.10 · Cited by 28 · see citing works

Whole Pichia pastoris Yeast Expressing Measles Virus Nucleoprotein as a Production and Delivery System to Multimerize Plasmodium Antigens

Jacob, D., Ruffié, C., Dubois, M., Combredet, C., Amino, R., Formaglio, P., Gorgette, O., Pehau‐Arnaudet, G., Guery, C., Mercereau‐Puijalon, O., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0086658 · Cited by 27 · see citing works

Yeast-surface expressed BVDV E2 protein induces a Th1/Th2 response in naïve T cells

Patterson, R., Nerren, J. R., Kogut, M. H., Court, P., Villarreal‐Ramos, B., Seyfert, H., Dalby, P. A., & Werling, D. (2011) · Developmental & Comparative Immunology · doi:10.1016/j.dci.2011.10.009 · Cited by 27 · see citing works

Uptake of various yeast genera by antigen-presenting cells and influence of subcellular antigen localization on the activation of ovalbumin-specific CD8 T lymphocytes

Bazan, S. B., Geginat, G., Breinig, T., Schmitt, M., & Breinig, F. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.07.141 · Cited by 27 · see citing works

Oral application of freeze-dried yeast particles expressing the PCV2b Cap protein on their surface induce protection to subsequent PCV2b challenge in vivo

Patterson, R., Eley, T., Browne, C., Martineau, H. M., & Werling, D. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.10.003 · Cited by 26 · see citing works

Heat treatment improves antigen-specific T cell activation after protein delivery by several but not all yeast genera

Bazan, S. B., Breinig, T., Schmitt, M., & Breinig, F. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.03.043 · Cited by 26 · see citing works

Generation of a prophylactic melanoma vaccine using whole recombinant yeast expressing MART‐1

Riemann, H., Takao, J., Shellman, Y. G., Hines, W. A., Edwards, C. K., Norris, D. A., & Fujita, M. (2007) · Experimental Dermatology · doi:10.1111/j.1600-0625.2007.00599.x · Cited by 25 · see citing works

A Phase 2 Randomized Placebo-Controlled Adjuvant Trial of GI-4000, a Recombinant Yeast Expressing Mutated RAS Proteins in Patients with Resected Pancreas Cancer

Muscarella, P., Bekaii-Saab, T., McIntyre, K., Rosemurgy, A., Ross, S. B., Richards, D. A., Fisher, W. E., Flynn, P. J., Mattson, A., Coeshott, C., et al. (2021) · Journal of Pancreatic Cancer · doi:10.1089/pancan.2020.0021 · Cited by 24 · see citing works

Molecularly Tailored Adjuvant Chemotherapy for Resected Non-small Cell Lung Cancer: A Time for Excitement and Equipoise

Azzoli, C. G., Park, B. J., Pao, W. J., Zakowski, M. F., & Kris, M. G. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31815efe24 · Cited by 24 · see citing works

Mutation-specific control of BCR-ABL T315I positive leukemia with a recombinant yeast-based therapeutic vaccine in a murine model

Bui, M. R., Hodson, V., King, T., Leopold, D., Dai, S., Fiolkoski, V., Oakes, S., Duke, R. C., Apelian, D., Franzusoff, A., et al. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.06.085 · Cited by 21 · see citing works

Immune-Modulating Vaccines in Non-small Cell Lung Cancer

Nemunaitis, J. J., & Murray, N. (2006) · Journal of Thoracic Oncology · doi:10.1016/s1556-0864(15)30401-9 · Cited by 20 · see citing works

Vaccines and Immunostimulants

Schlom, J., Gulley, J. L., & Hodge, J. W. (2017) · Holland‐Frei Cancer Medicine · doi:10.1002/9781119000822.hfcm066 · Cited by 20 · see citing works

Clinical trials of vaccines for immunotherapy in pancreatic cancer

PLATE, J. M. D. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.77 · Cited by 19 · see citing works

Lyophilized yeast powder for adjuvant free thermostable vaccine delivery

Kumar, R., & Kharbikar, B. N. (2021) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-021-11259-1 · Cited by 19 · see citing works

Baker's yeast expressing the Japanese encephalitis virus envelope protein on its cell surface: induction of an antigen‐specific but non‐neutralizing antibody response

Upadhyaya, B., & Manjunath, R. (2009) · Yeast · doi:10.1002/yea.1676 · Cited by 18 · see citing works

Inducing Efficient Cross-priming Using Antigen-coated Yeast Particles

Howland, S. W., Tsuji, T., Gnjatic, S., Ritter, G., Old, L. J., & Wittrup, K. D. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318181c87f · Cited by 17 · see citing works

Genetically modified cancer vaccines: Current status and future prospects

Hu, X., Zhou, W., Pi, R., Zhao, X., & Wang, W. (2022) · Medicinal Research Reviews · doi:10.1002/med.21882 · Cited by 15 · see citing works

Emerging Frontiers in Colorectal Cancer Therapy: From Targeted Molecules to Immunomodulatory Breakthroughs and Cell-Based Approaches

Fatemi, N., Mirbahari, S. N., Tierling, S., Sanjabi, F., Shahrivari, S., AmeliMojarad, M., AmeliMojarad, M., Rezaei, M. M., Nobaveh, P., Totonchi, M., et al. (2025) · Digestive Diseases and Sciences · doi:10.1007/s10620-024-08774-2 · Cited by 13 · see citing works

GI-19007, a Novel Saccharomyces cerevisiae-Based Therapeutic Vaccine against Tuberculosis

King, T. H., Shanley, C. A., Guo, Z., Bellgrau, D., Rodell, T. C., Furney, S. K., Henao-Tamayo, M. I., & Orme, I. M. (2017) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00245-17 · Cited by 13 · see citing works

Advanced Pancreatic Cancer: Flourishing Novel Approaches in the Era of Biological Therapy

Chiu, J. W. Y., Wong, H., Leung, R. C.-Y., Pang, R. W. C., Cheung, T. T., Fan, S.-T., Poon, R. T. P., & Yau, T. C. C. (2014) · The Oncologist · doi:10.1634/theoncologist.2012-0131 · Cited by 9 · see citing works

Current Immunotherapeutic Strategies in Pancreatic Cancer

PLATE, J. M. D. (2007) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2007.07.012 · Cited by 9 · see citing works

IL-6-inducing Whole Yeast-based Immunotherapy Directly Controls IL-12-dependent CD8 T-cell Responses

Tamburini, B. A. J., Kedl, R. M., & Bellgrau, D. (2011) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3182356888 · Cited by 8 · see citing works

Toward a molecular explanation for cross-presentation of antigens to the immune system.

Khor, B., & Makar, R. (2008) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2008.02.002 · Cited by 10 · see citing works

Therapeutic cancer vaccines in the treatment of non-small-cell lung cancer

Limacher, J., Spring-Giusti, C., Bellon, N., Ancian, P., Rooke, R., & Bonnefoy, J. (2013) · Expert Review of Vaccines · doi:10.1586/erv.13.14 · Cited by 7 · see citing works

New and potential clinical applications ofKRASas a cancer biomarker

Kriegshäuser, G., Auner, V., & Zeillinger, R. (2010) · Expert Opinion on Medical Diagnostics · doi:10.1517/17530059.2010.510512 · Cited by 7 · see citing works

Construction and application of a yeast expression system for thymosin α1

FENG*, C., XIANG-MING**, C., ZHI*, C., Jiang, H., Xiao-ping, P., ZHONG-RONG, H., Liu, R., & Chen, X. (2005) · Biocell · doi:10.32604/biocell.2005.29.253 · Cited by 7 · see citing works

Cancer vaccines: Clinical development challenges and proposed regulatory approaches for patient access to promising treatments

Stebbing, J., Wood, C. G., Atkins, M. B., Bukowski, R. M., Litwin, S., Bower, M., Parsa, A. T., & Levitsky, H. I. (2008) · Cancer · doi:10.1002/cncr.23273 · Cited by 5 · see citing works

T-Cell-Mediated Immunity and Immunotherapy of Chronic Hepatitis C

Duke, R. C., Franzusoff, A., & Apelian, D. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-565-7_19

Development of Vaccine Therapy for Pancreas Cancer

Le, D. T., Jaffee, E. M., & Laheru, D. A. (2008) · Springer eBooks · doi:10.1007/978-0-387-69252-4_41

Comparative study of using different yeast genera as vehicles for protein delivery to antigen-presenting cells

Bazan, S. B. (2011) · Publications of the UdS (Saarland University) · doi:10.22028/d291-22748

Anticancer Immunotherapy: Prospects and Challenges

Sachdeva, R., Singh, P., Bose, A., Kalha, B., Sarkar, M., & Pal, R. (2019) · Springer eBooks · doi:10.1007/978-981-32-9816-3_8

Current awareness on yeast

(2005) · Yeast · doi:10.1002/yea.1158

Current awareness on yeast

(2003) · Yeast · doi:10.1002/yea.1083

Vaccines and Immunomodulators

Schlom, J., Gameiro, S. R., Palena, C., & Gulley, J. L. (2022) · Holland‐Frei Cancer Medicine · doi:10.1002/9781119000822.hfcm066.pub2

Treatment of Ras mutation-bearing solid tumors using whole recombinant S. cerevisiae yeast expressing mutated Ras: Preliminary safety and immunogenicity results from a phase 1 trial

Cohn, A. L., Morse, M. A., O’Neil, B. H., Bellgrau, D., Duke, R. C., Franzusoff, A., Munson, S. H., Ferraro, J., & Rodell, T. C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.2571 · Cited by 17 · see citing works

Abstract A28: Immune responses to mutated Ras - development of a yeast-based immunotherapeutic

Coeshott, C. M., Holmes, T., Mattson, A., King, T., Guo, Z., Cohn, A. L., & Rodell, T. C. (2014) · Molecular Cancer Research · doi:10.1158/1557-3125.rasonc14-a28 · Cited by 8 · see citing works

A Phase I Vaccine Trial with Peptides Reflecting ras Oncogene Mutations of Solid Tumors

Khleif, S. N., Abrams, S. I., Hamilton, J. M., Bergmann‐Leitner, E. S., Chen, A. P., Bastian, A., Bernstein, S. A., Chung, Y., Allegra, C. J., & Schlom, J. (1999) · Journal of Immunotherapy · doi:10.1097/00002371-199903000-00007 · Cited by 125 · see citing works

Whole recombinant Saccharomyces cerevisiae yeast expressing Ras mutations as treatment for patients with solid tumors bearing Ras mutations: Results from a phase 1 trial

Cohn, A., Morse, M. A., O’Neil, B., Whiting, S., Coeshott, C., Ferraro, J., Bellgrau, D., Apelian, D., & Rodell, T. C. (2018) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000219 · Cited by 41 · see citing works

Induction of T-Cell Immunity Against Ras Oncoproteins by Soluble Protein or Ras-Expressing Escherichia coli

Fenton, R. G., Keller, C. J., Hanna, N., & Taub, D. D. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.24.1853 · Cited by 42 · see citing works